Posttransplant Malignancy

Ana P Rossi; Christina L Klein

doi:10.1016/j.suc.2018.09.004

Posttransplant Malignancy

Surg Clin North Am. 2019 Feb;99(1):49-64. doi: 10.1016/j.suc.2018.09.004.

Authors

Ana P Rossi¹, Christina L Klein²

Affiliations

¹ Maine Medical Center, Maine Transplant Program, 19 West Street, Portland, ME 04102, USA. Electronic address: [email protected].
² Department of Transplantation, Piedmont Transplant Institute, Piedmont Atlanta Hospital MTP Mason Transplant, 1968 Peachtree Road Northwest, Building 77, Atlanta, GA 30309, USA.

PMID: 30471741
DOI: 10.1016/j.suc.2018.09.004

Abstract

Posttransplant malignancy is a leading cause of death after solid organ transplantation (SOT). Recipients of SOT are at significantly higher risk of multiple cancers compared with the general population, most notably nonmelanoma skin cancer and posttransplant lymphoproliferative disorders. Risk factors for posttransplant malignancy include history of malignancy, immunosuppression, oncogenic viral infections, sun exposure, and disease-specific associations. Early detection and treatment of malignancies can improve survival.

Keywords: Cancer; Cancer screening; Malignancy; Solid organ transplant; Transplantation.

Publication types

Review

MeSH terms

Humans
Immunosuppression Therapy
Neoplasms / etiology*
Organ Transplantation / adverse effects*
Risk Factors